Comparative Pharmacology
Head-to-head clinical analysis: OXILAN 350 versus RENOCAL 76.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXILAN 350 versus RENOCAL 76.
OXILAN-350 vs RENOCAL-76
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iodinated contrast medium that attenuates X-rays due to its iodine content, enhancing vascular and tissue contrast during imaging. It distributes in extracellular fluid and is freely filtered by glomeruli.
Contains iothalamate meglumine, an ionic high-osmolar contrast medium that absorbs X-rays, thereby enhancing vascular and tissue contrast during radiographic procedures. It functions by increasing the attenuation of X-rays in blood and tissues where it distributes.
Intravenous: 0.5–2 mL/kg (350 mg I/mL) for CT imaging; maximum 200 mL total. Intra-arterial: 0.3–1.5 mL/kg per injection; maximum 200 mL per procedure.
Intravenous: 50-100 mL of a 37% iodine-containing solution (approximately 14-28 g iodine) administered as a slow intravenous injection over 1-2 minutes, or as an intravenous infusion over 10-30 minutes, typically not exceeding 4.5 mL/kg body weight.
None Documented
None Documented
Terminal elimination half-life: 2 hours (normal renal function); prolonged in renal impairment (up to 24 hours in severe impairment).
Terminal elimination half-life ranges from 1.2 to 2.5 hours in patients with normal renal function. In patients with severe renal impairment, half-life may be prolonged up to 20 hours.
Renal: >90% unchanged drug within 24 hours; Biliary/fecal: <2%
Primarily renal excretion via glomerular filtration. Approximately 95% of administered dose is excreted unchanged in urine within 24 hours. Less than 5% undergoes biliary/fecal elimination.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent